Report on the risk assessment of methyl 2-[[1-(cyclohexylmethyl)-1H-indole-3-carbonyl]amino]-3,3-dimethylbutanoate (MDMB-CHMICA) in the framework of the Council Decision on new psychoactive substances

This publication presents the data and findings of the risk assessment on methyl 2-[[1-(cyclohexylmethyl)-1H-indole-3-carbonyl]amino]-3,3-dimethylbutanoate (MDMB-CHMICA), carried out by the extended Scientific Committee of the EMCDDA on 22 July 2016. MDMB-CHMICA is the first synthetic cannabinoid receptor agonist to be risk-assessed by the EMCDDA. On the basis of the Risk Assessment Report — and on the initiative of the European Commission — on 27 February 2017, the Council decided that MDMB-CHMICA should be subject to control measures across the Member States.